Overview

Study of E7389 in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.